A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

Inclusion Criteria:

* The age is 18-70 years old.
* The written informed consent of the patient / legal representative is obtained before any program related implementation.
* Metastatic or non resectable, locally advanced gastric or gastroesophageal adenocarcinoma, confirmed by histology or cytology.
* The development of objective imaging after first-line chemotherapy (RECIST1.1);
* There were measurable lesions (according to RECIST1.1);
* Can provide tumor tissue specimens;
* PDL1 positive (only for the second, third stage) or MSI test positive;
* Time interval to last chemotherapy is at least 1 month.
* 0-1 ECOG score
* The expected survival time is more than 4 months
* Peripheral blood cell culture showes the proliferation of lymphocytes

Exclusion Criteria:

* Participate in the plan or implementation of the research (including staff of HRYZ and the staff of the research center);
* Participate into other clinical studies at the same time, unless it is an observational (non - intervention) clinical study;
* Subjects may receive other systemic antitumor treatment during the study.
* Squamous or undifferentiated gastric cancer
* There were active bleeding, ulcers, gastrointestinal perforation, fistula, or arterial embolism in the gastrointestinal tract within 6 months.
* There were clinically significant gastrointestinal bleeding or venous thrombosis in three months before enrollment.
* End-stage cachexia patients;
* Patients with severe coagulation dysfunction;
* Patients with extensive abdominal adhesions;
* Patients with intestinal obstruction;
* Pregnancy or planned pregnancy;
* Refusing to provide blood specimens;
* Hypersensitivity to sodium citrate;
* Subjects have received allogeneic transplantation
* Subjects had clinical symptoms of central nervous system metastasis (such as brain edema, requiring hormone intervention, or progression of brain metastases)
* Subjects are using immunosuppressive agents, or whole body or absorbable local hormone therapy to achieve the aim of immunosuppression (dose \>10mg/ days prednisone or other therapeutic hormones) and continue to use in the first 2 weeks before enrollment.
* Systemic or long-term application of immunomodulators, such as interferon, thymosin, and immunosuppressive drugs, in half a year.
* Subjects had been treated with MASCT or other cellular immunotherapy within a year.
* Subjects had any active autoimmune disease or a history of autoimmune disease.
* Active tuberculosis
* There is a big operation in 30 days before the first study treatment.
* Patients with active hepatitis B virus (HBV) infection (chronic or acute)
* The infection of active hepatitis C virus (HCV)
* Suffering from human immunodeficiency virus (HIV) or syphilis
* A history of peripheral nervous system disorder or a history of obvious mental disorders and central nervous system disorders
* Subjects had active infection or \>38.5 degree of unexplained fever in the screening period and before the first administration.
* Chronic systemic diseases, such as liver disease (such as cirrhosis, etc.), kidney disease, respiratory disease, or non controlled diabetes, hypertension, etc.
* There were other malignant tumors in 5 years, except for non melanin skin cancer and cervical carcinoma in situ
* There are heart symptoms or diseases that have not been well controlled.
* Subjects were known to have a history of psychotropic drug abuse, alcoholism, or drug abuse.
* According to the researchers, there are other factors that may lead to a halt.